Feb. 14, 2013
-based Medizone International (MZEI:OB MZEI:QB), announced today the successful completion of safety and preliminary operational trials of its AsepticSure system at
Quinte Health Care Belleville General Hospital
, affiliated with Queen's University.
Working with Contamination Control Company (C3), an
-based provider of AsepticSure services in
, Medizone has unequivocally demonstrated the safety and ease of operation of its AsepticSure® disinfection process in a functioning health care setting. Room turnaround times were less than 90 minutes.
Michael E. Shannon
, Medizone's Director of Medical Affairs stated, "Quinte Health Care
an excellent HAI record, and to demonstrate success at one of their busy, acute community hospitals is extremely encouraging. It is becoming increasingly obvious that the introduction of AsepticSure into the healthcare industry will be seen as a breakthrough that could lead to hospitals achieving levels of infection prevention and control not considered possible, until now.
"AsepticSure will be establishing a new gold standard in the continuing quest for excellence in patient safety and quality health care. This notion is supported by the great ease-of-use and compatibility that the system demonstrated at QHC Belleville General Hospital.
"With these first
phases of our test program at Quinte Health Care now successfully completed," said Shannon, "we're preparing to tackle infection control problems that have proven to be an 'almost impossible' challenge to modern cleaning processes at every hospital on this continent."
For press information on Medizone International, please contact:
, Investor Relations, Medizone International, Inc.
T: 001-415-331-0202 E:
Medizone International, Inc. is engaged in initial production of its modular design AsepticSure
Decontamination Systems. Decontamination to the sterilization standard of >6 log (99.9999%) is obtainable within hospitals, airlines, cruise ships, long term care facilities, food processing plants, clean room manufacturing facilities, schools and other critical infrastructure.
This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.